News

The study, which is the first of two double-blind trials in the FIT Phase 3 clinical program, demonstrated that 18% of patients receiving fostamatinib achieved a stable platelet

These minutes confirmed the FDA’s acceptance of Tonix’s proposed Phase 3 studies and the planned New Drug Application (NDA) data package to support the registration of TNX-102 SL

The study met all primary and secondary endpoints at 12 months. The data showed that treatment with Prolia for 12 months, compared to risedronate, led to significantly greater

The PERSIST-2 trial demonstrated statistically significant improvement in spleen volume reduction (SVR) with pacritinib compared to best available therapy (BAT), including ruxolitinib. The results were generated from 221

The double-blind and placebo-controlled clinical study involving 40 healthy volunteers demonstrates the safety of topically applying FS2 cream at the maximum feasible dose with no adverse effects. The

The Company is issuing this press release to provide further heightened awareness of this recall and to provide instructions to consumers, pharmacists, and wholesalers in possession of the

Synacthen Depot is a depot formulation of Synacthen (tetracosactide), a synthetic 24 amino acid melanocortin receptor agonist. It is approved and marketed outside the US for several autoimmune

ND0612L is a low-dose continuous subcutaneously administered levodopa/carbidopa liquid formulation.  Parkinson’s disease is a progressive neurodegenerative illness characterized by reduced dopamine levels in the brain. The multicenter, double-blind, placebo-controlled

Utilizing Ironshore’s proprietary delayed-release and extended-release technology, DELEXIS, HLD100 is intended for nighttime dosing and is designed to control ADHD symptoms and improve functioning immediately upon awakening and